EUVIMEDDécouvrir EUVIMED
Open access · CC BY 4.0

Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases

Takayuki Niitsu iD, Toshiaki Kataoka, Kiyoharu Fukushima, Daisuke Motooka, Shigeyuki Shichino, Yayoi Natsume-Kitatani, Hideya Kitamura, Takashi Niwa, Tomohisa Baba, Daisuke Okuzaki iD, Atsushi Kumanogoh, Shizuo Akira and 2 more

The Journal of Pathology · 2025-09 · 267 (1) · 79-91

DOI: 10.1002/path.6451 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2025-07-28. Written by Takayuki Niitsu and 13 co-authors. Institution: Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan. Major MEDLINE topics: Osteonectin, Lung Diseases, Interstitial, Transcriptome, Lung. Cited 5 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Health, Labour and Welfare, Cabinet Office of Japan Government for the Public/Private R&D Investment Strategic Expansion PrograM.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Interstitial lung diseases (ILDs) encompass a diverse group of pulmonary disorders, with progressive fibrosis leading to poor prognosis. Here we aimed to identify key molecules involved in progressive fibrosis across various ILDs, using spatial transcriptomics (ST). ST analysis (Visium) was performed on lung cryobiopsy specimens from five patients with various ILDs. Two cases, rich in young fibrotic lesions, as defined by fibroblastic foci and destructive alveolar organization, were selected for spatial high‐dimensional weighted gene coexpression network analysis (hdWGCNA) to identify key gene networks with biological significance in active fibrosis. We utilized public single‐cell RNA sequencing datasets of various ILDs, performed enrichment analysis and trajectory‐based differential expression analysis, and quantified cell–cell communication to evaluate the involvement of the spatially extracted module in fibrosis. Immunohistochemical staining of the extracted molecules was performed. Using hdWGCNA, we identified a distinct gene module (the SM2 module) enriched in young fibrotic lesions. The SM2 module was characterized by distinct features of fibroblast activation that were represented across various lesions. Key hub genes within this module, including COL1A2 , COL3A1 , COL1A1 , and SPARC , formed a robust coexpression network. Immunohistochemical staining showed that SPARC, a component of the SM2 module, was highly expressed in young fibrotic lesions, but not in old scarring lesions, across various ILDs. To assess the prognostic significance of SPARC immunohistochemical expression, we extended our analysis to a cohort of 71 patients with unclassifiable ILDs (uILDs), a particularly heterogeneous subtype with unclear pathogenesis and limited treatment options. Higher SPARC levels in the upper, lower, or both lung lobes in uILD were significantly associated with poor overall survival. In summary, an integrated cross‐disease approach using ST revealed key gene expression patterns central to active fibrosis and successfully identified SPARC as a potentially beneficial prognostic marker. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

OsteonectinLung Diseases, InterstitialTranscriptomeLungHumansPrognosisMaleFemaleGene Expression ProfilingMiddle AgedAgedBiomarkersGene Regulatory Networks

Author keywords

SPARCfibrosisinterstitial lung diseases (ILDs)single‐cell RNA sequencing (scRNA‐seq)spatial transcriptomics (ST)unclassifiable ILDs (uILDs)

Substances

OsteonectinSPARC protein, humanBiomarkers

Authors and institutions

  • Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Laboratory of Host Defense, World Premier Institute Immunology Frontier Research Center (WPI-IFReC), Osaka University, Osaka, Japan.
  • Department of Pathology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
  • Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.
  • Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan.
  • National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.

ORCID profiles: Takayuki Niitsu, Daisuke Okuzaki

Funding

  • Ministry of Health, Labour and Welfare
  • Cabinet Office of Japan Government for the Public/Private R&D Investment Strategic Expansion PrograM

Cite

APA

Niitsu, T., Kataoka, T., Fukushima, K., Motooka, D., Shichino, S., Natsume-Kitatani, Y., Kitamura, H., Niwa, T., Baba, T., Okuzaki, D., Kumanogoh, A., Akira, S., Okudela, K., & Ogura, T. (2025). Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases. The Journal of Pathology, 267(1), 79-91. https://doi.org/10.1002/path.6451

Vancouver

Niitsu T, Kataoka T, Fukushima K, Motooka D, Shichino S, Natsume-Kitatani Y, et al. Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases. The Journal of Pathology. 2025;267(1):79-91. doi:10.1002/path.6451

BibTeX
@article{Niitsu2025,
  author = {Niitsu, Takayuki and Kataoka, Toshiaki and Fukushima, Kiyoharu and Motooka, Daisuke and Shichino, Shigeyuki and Natsume-Kitatani, Yayoi and Kitamura, Hideya and Niwa, Takashi and Baba, Tomohisa and Okuzaki, Daisuke and Kumanogoh, Atsushi and Akira, Shizuo and Okudela, Koji and Ogura, Takashi},
  title = {Spatial transcriptomics identifies SPARC as a prognostic marker in interstitial lung diseases},
  journal = {The Journal of Pathology},
  year = {2025},
  volume = {267},
  number = {1},
  pages = {79--91},
  doi = {10.1002/path.6451}
}
Start for free →